Social Media Ideas for Fbnrx

Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg...

Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer

This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.

SFM

SFM Anonymous (not verified) Wed, 06/10/2026 - 20:50 field_thread_url https://cafepharma.com/boards/threads/sfm.701491/ board name...

argenx: The FcRn Franchise Is Becoming An Autoimmune Operating System

Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market

Yes, many of the companies you've invested in also have their own stock portfolios. This is bullishness worth noting.

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch

Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.

SFM

SFM Anonymous (not verified) Sun, 06/14/2026 - 20:54 field_thread_url https://cafepharma.com/boards/threads/sfm.701491/ board name...

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

GRS Advisors Opens $49 Million Broadstone Net Lease Position, According to Recent SEC Filing

Broadstone Net Lease has the steady rent base investors expect from long-term tenant contracts. The next question is whether new property investments can turn that stability into p...

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing

Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing

Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.

FTAI Infrastructure (FIP) Expects More Than $300 Million in Net Proceeds from Long Ridge Deal

Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript

Frontier Nuclear gets Nasdaq non-compliance notice over missing Form 6-K filing

RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)

<![CDATA[Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Be...